Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Elblag – page 6

120 clinical trials in Elblag, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Elblag at a glance
120
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

120 trials in Elblag

Open in trial search

Osteoporosis

Not recruiting

Study Comparing MAB-22 and Denosumab for Treating Osteoporosis in Postmenopausal Women

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Xentria Inc.

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Osteoarthritis

Not recruiting

Study on the Safety of RTX-GRT7039 and Ropivacaine Hydrochloride Injections for Patients with Moderate to Severe Knee Osteoarthritis Pain

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Resiniferatoxin
  • Sponsor:Gruenenthal GmbH

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not recruiting

Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 kappa monoclonal antibody against interleukin 18
  • Sponsor:Glaxosmithkline Research & Development Limited

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Rosnilimab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab
  • Sponsor:Anaptysbio Inc.

Psoriasis

Not recruiting

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Dr Reddy's Laboratories Limited

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Asthma

Not recruiting

Study of Different Doses of Amlitelimab Given by Injection Under the Skin in Adults with Moderate to Severe Asthma

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Elblag

What the registry says about research in the country

01 Dermatological Conditions

Research focusing on plaque psoriasis and innovative treatments for moderate to severe cases. Studies evaluating novel therapeutic approaches for atopic dermatitis.

  • Moderate to Severe Plaque Psoriasis
  • Atopic Dermatitis Management

Multiple trials investigating long-term safety and efficacy of new therapeutic agents.

02 Rheumatological Studies

Comprehensive research into psoriatic arthritis treatments, including studies for both biologic-naive and experienced patients. Additional focus on Sjögren's Syndrome and innovative therapies.

  • Active Psoriatic Arthritis
  • Primary Sjögren's Disease
  • Rotator Cuff Tendinopathy

Evaluating multiple therapeutic approaches for autoimmune conditions.

03 Metabolic and Respiratory Research

Studies addressing obesity and weight management through innovative treatments. Research on respiratory conditions including RSV infections and asthma management.

  • Obesity and Weight Management
  • Respiratory Syncytial Virus
  • Asthma Control

Focus on both preventive measures and therapeutic interventions.

04 Gastrointestinal Studies

Investigations into treatments for Crohn's Disease and Ulcerative Colitis, focusing on innovative therapeutic approaches for inflammatory bowel conditions.

  • Moderately to Severely Active Crohn's Disease
  • Ulcerative Colitis Management

Evaluating new therapeutic options for inflammatory bowel diseases.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.